Product information:
- Molecular formula – C187H291N45O59
- Molecular mass – 4114 g·mol−1
Other names:
- Semaglutide
- NN9535
- Ozempic
- Rybelsus
- 910463-68-2
Discovery:
Semaglutide belongs to the class of medicines called the GLP-1 receptor agonists. These medicines replicate the GLP-1 that helps in lowering blood glucose levels. Moreover, it also helps in reducing appetite. A group of scientists at Novo Nordisk developed semaglutide in 2012. This was called the GLP-1. The subsequent research led to the approval of Semaglutide by the FDA in June 2021.
Mechanism of action:
Semaglutide works by increasing the efficiency of incretin by activating the GLP-1 receptors. There are several mechanisms through which Semaglutide works. This includes
- augmentation of insulin secretion
- inhibition of glucagon release
- suppression of hepatic gluconeogenesis
All of these mechanisms eventually help reduce fasting and post-prandial glucose. Furthermore, Semaglutide also helps improve the efficiency of β- cell functioning and insulin production. The overall reduction of body weight mediates the improvement in insulin sensitivity.
Clinical Applications of Semaglutide:
Type 2 Diabetes
Ever since the approval of glucagon-like peptide-1 receptor agonists, Semaglutide has become the preferred choice for the management of type-2 diabetes. This is because it has a minimum risk of hypoglycemia and weight loss. Additionally, it has cardiovascular benefits. It can significantly reduce HbA1c levels, promote weight loss, and improve cardiovascular outcomes. Semaglutide can be used as monotherapy or in combination with other antidiabetic medications to achieve target HbA1c levels in patients.
Non-Alcoholic fatty liver disease
Non-Alcoholic fatty liver disease is a commonly occurring liver disease complicated by diabetes. If left untreated, these diseases can develop into liver cirrhosis and carcinoma. Recently, Semaglutide has been shown to improve NAFLD by affecting the pancreatic cells. Furthermore, it also improves impaired liver function, hypertriglyceridemia, and insulin resistance. There is also marked improvement in the liver fibrosis markers, which indicates that it may be beneficial in such cases too.
Semaglutide and weight loss
Semaglutide has also been studied for its potential use in weight loss.
Research has shown that Semaglutide can be effective in helping people lose weight. In a clinical trial called STEP 1, participants who took Semaglutide lost an average of 15.3% of their body weight over 68 weeks, compared to 2.4% in the placebo group. In another trial called STEP 2, participants who took semaglutide lost an average of 17.4% of their body weight over 68 weeks, compared to 5.7% in the placebo group.
Semaglutide works by mimicking the effects of the hormone GLP-1, which regulates appetite and food intake. It slows down the rate at which food leaves the stomach, which makes people feel fuller for longer periods of time. It also reduces the amount of glucose that the liver produces, which can help with weight loss.
Disclaimer
The information provided about Semaglutide in this section is only for research advancement and disbursement of knowledge. The material collected in this article is meant for informational purposes about Semaglutide. It is not to be considered instructional in any way. Moreover, we have further empathized with this by making sure no dosage information of Semaglutide or recommendations about its way of consumption is mentioned. The information available in this article is a collection from different recognized studies and researches conducted by known experts and researchers in controlled medical facilities and institutions. Furthermore, the information provided in the article is not to encourage the reader to start its consumption or as an advertisement of the product. Administering any supplement or medication not FDA approved may be harmful and may cause serious illness. Peptide Pros insist that none of their products be ingested under any circumstances.
References:
- https://pubchem.ncbi.nlm.nih.gov/compound/Semaglutide
- https://en.wikipedia.org/wiki/Semaglutide
- Semaglutide| DB13928|go.drugbank|https://go.drugbank.com/drugs/DB13928
- Goldenberg, Ronald M., and Oren Steen. “Semaglutide: review and place in therapy for adults with type 2 diabetes.” Canadian journal of diabetes 43.2 (2019): 136-145.
- Arai, T., Atsukawa, M., Tsubota, A., Ono, H., Kawano, T., Yoshida, Y., … & Iwakiri, K. (2022). Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. JGH Open, 6(7), 503-511.
- https://clinicaltrials.gov/ct2/show/NCT03548935
- https://clinicaltrials.gov/ct2/show/NCT03552757
Where to find Semaglutide for sale?
If you’re looking to buy Semagutide online for research purposes, shop at Peptide Pros, the most reliable supplier of the highest quality SARMS and USA peptides for sale: https://www.peptidepros.net/product/semaglutide-3mg/